Article | April 9, 2024

Pharmaceutical Solid-State Studies

Source: Alcami
GettyImages-1087219020 Scientists wearing protective coveralls working in manufacturing laboratory

Physicochemical characterization of an active pharmaceutical ingredient (API) in preclinical development is one of the major activities supporting the investigational new drug (IND) application. Furthermore, obtaining the physicochemical profile is key to understanding the API performance attributes, (e.g., absorption, stability, processability) and in setting the direction of the formulation design.

The physical properties assessed for APIs include crystallinity, polymorphic form, particle size and habit, melting and decomposition temperatures, solvent content, and hygroscopicity. A specialized single-crystal X-ray structure determination that proves the atomic connectivity, enhances the understanding of the solidstate nature and strengthens the regulatory and legal filings may also be pursued.

In addition to solid-state assessment, solubility, and stability (both chemical and physical) as a function of pH are determined in aqueous buffers. These data are utilized to determine pKa and the amenability of the API to form salts. Furthermore, solubility data are also obtained in media relevant to the administration route. For oral solid dosages (OSDs), dissolution in water and simulated biorelevant (salivary, gastric, and intestinal) fluids are considered in the context of solubility, or dissolution-rate limited absorption, using the Biopharmaceutical and Developability Classification Systems (BCS/DCS). For solution dosages, which often support toxicological studies and parenteral formulations, solubility in water, co-solvent, and solubilizing agents is obtained.

The knowledge of the polymorphic landscape and the physical stability of the progressed solid form in the relevant solvents/media is required, irrespective if the intended formulation is solid or liquid. Therefore, solids isolated from pH solubility or biorelevant solubility studies are analyzed to determine if a conversion occurred to a more stable hydrate, or in the case of salts, to disproportionated pure free form or counterion. For solution formulations, it is important to ensure that the drug concentration is below the equilibrium solubility of the most stable solid-state form in that formulation.  

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online